: Summary of genomics and functional properties for all T2D interactome signatures. T2D interactome signatures overlapping with various genomics and functional properties are defined as follows: "DGE in T2D pancreatic/muscle/liver" indicates the signatures were also dysregulated in T2D relevant tissues, in addition to our discovery cohort; "Chromatin-folding" indicates the genes which may be distantly regulated by the GWAS SNPs reaching genome-wide significance in DIAGRAM-database; "GWAS + cis-, trans-eQTL" refers to the genes identified by the Sherlock statistical framework to be associated to T2D with the use of DIAGRAM-database, cis-and trans-eQTL signals; "cis-eQTL" refers to the SNPs in perfect LD to T2D interactome signatures with eQTL properties regulating these genes; "Comorbidity" refers to genes that are shared between T2D and comorbid diseases; "Druggability" indicates T2D druggable or potentially druggable targets; "Insulin & T2D-GWAS" refers to genes in the insulin pathway and T2D genes in GWAS Catalogue dysregulated in the T2D interactome signatures. The T2Di signatures overlapped with genomics and functional properties were considered to be higher confident set (HC), and those without were considered as the lower confidence set (LC). Menche et al. 25%
de novo prediciton (co-expression) in this study 6%
Kalathur et al. 65% Figure S5 . Distribution of interaction sources in T2D interactome. The gene network information of the T2Di were assembled from peer reviewed publicaitons shown in the references below, and also predicted using ARACHE based on co-expression patterns using RNA-Seq data generated in this study. Comparison of T2D association probability between T2Di signatures, T2D-GWAS genes and randomized gene sets. The 10 set of randomized genes showed lower median probability association scores to T2D than the established GWAS genes and T2Di signature. 
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